FetTech is a regenerative medicine company focused on advancing the body’s natural ability to heal by developing innovative, FDA-cleared tissue repair technologies. At the heart of their work is the Multi-Tissue Platform (MTP®), a unique biomaterial that combines components from multiple tissue types to deliver a broad range of healing signals. This approach goes beyond traditional single-source extracellular matrix (ECM) products by offering a more complete set of proteins, growth factors, and structural elements needed for complex tissue repair.
Founded by husband-and-wife team Clay and Danielle Fette, FetTech blends scientific innovation with a patient-first philosophy. Their company remains privately owned, allowing them to prioritize research, clinical results, and ethical practices over outside pressure.
FetTech’s technologies are already used in wound care, burn treatment, surgery, and aesthetic medicine through specialized product lines like StemSys (powders), ReyaGel (liquids), and VyraMed (antiviral applications). With ongoing research into nerve, heart, and immune system regeneration, FetTech is committed to reshaping the future of healing by restoring the body’s full regenerative potential.